Drug intelligence / Profile preview

DW6014

Development stage: Phase 1
Lead developer: Dongwha Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

DW6014 is a fixed-dose combination drug developed by Dong Wha Pharmaceutical Co., Ltd. It consists of empagliflozin and metformin in an extended-release formulation. Empagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor, which reduces glucose reabsorption in the kidney, while metformin is a biguanide that decreases hepatic gluconeogenesis and increases insulin sensitivity. The combination is intended for the treatment of type 2 diabetes mellitus[5][3][4].

Other names: empagliflozin + metformin

Targets

AMPK (Adenosine monophosphate–activated protein kinase)SGLT2 (Sodium-glucose cotransporter protein subunit 2)

Beyond the preview

Go deeper on DW6014.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DW6014.

Explore the full profile